Indolent B-Cell Lymphoma
The latest news, research, and perspectives in indolent B-cell lymphoma. This diverse group of slow-growing non-Hodgkin lymphomas form in B cells and include follicular lymphoma, hairy cell leukemia, and marginal zone lymphoma.
Advertisement
The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases.
The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies.
The panel discusses treatment sequencing after CAR-T or transplant and the role bispecifics and other regimens may play.
The panel discusses combination therapy options for patients with DLBCL and FL.
The panel discusses novel treatment options for FL, including bispecifics, CAR-Ts, monoclonal antibodies, and more.
The panel talks about novel therapies for DLBCL, including the timing and sequencing for such treatments and more.
Advertisement
The panel discusses barriers to improving treatment options for patients with DLBCL and follicular lymphoma.
A panel discusses the unmet needs and emerging therapeutic areas for DLBCL and follicular lymphoma.
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse.
Manali Kamdar, MD; and Craig S. Sauter, MD, FACP; debate CAR T-cell therapy and AHSCT in second-line DLBCL.
Patients with LBCL received prophylactic anakinra to reduce the risk of cytokine release syndrome following CAR-T.
Orelabrutinib monotherapy may be an option for relapsed/refractory Waldenström’s macroglobulinemia.
Eighty percent of patients with marginal zone lymphoma (MZL) experienced tumor response with zanubrutinib monotherapy, ...
Umbralisib was approved to treat marginal zone lymphoma (MZL) and follicular lymphoma (FL).
The U.S. Food and Drug Administration (FDA) has granted tisagenlecleucel accelerated approval for adult patients with ...
The regimen improved overall survival in patients with MYC-translocated lymphomas.
Clinicians are excited to see how many patients could benefit with CAR T-cell therapy.
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Allogene Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to resume trials of its allogeneic ...
After failing to complete the requisite confirmatory trials following accelerated approval, Gilead has announced it will ...
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726